Neurosurgery Institute, Key Laboratory on Brain Function Repair and Regeneration of Guangdong, Southern Medical University, Guangzhou, 510282, China.
Cell Mol Neurobiol. 2010 Aug;30(6):955-60. doi: 10.1007/s10571-010-9525-9. Epub 2010 Jun 6.
Brain tumor stem-like cells (BTSLCs) have been implied to play an important role in genesis and development of glioma. However, their characteristics on proliferation and drug-resistance are uncertain thoroughly. In this experiment, some of the biological characteristics about BTSLCs were explored. Twenty cases of different grades of human glioma tissues were obtained from clinic. The primary glioma cells were collected and CD133(+) cells from them were purified by magnetic cell sorting assay. The BTSLCs were identified by testing the expression of CD133, Nestin, NSE, and GFAP, along with the culture process. WST-8 assay kit was used to evaluate the proliferating situation of CD133(+) cells in the different grade gliomas, and to compare the drug-resistance between the CD133(+) and CD133( - ) cells in the medium containing different concentrations of teniposide (VM-26). The results showed that the CD133(+) cells could regenerate by self-renewal, then generate and different into NSE(+) and GFAP(+) cells, respectively. CD133(+) cells in the high grade of gliomas showed the faster generation than the ones in the low grade. The number of survived CD133(+) cells in the medium containing VM-26 was much more than the CD133(-) ones in it. Therefore, it was implied that the CD133(+) BTSLCs existed in the glioma tissues possessed the more tolerant ability to the VM-26, and could proliferate much more easily in the high-grade glioma.
脑肿瘤干细胞样细胞(BTSLCs)被认为在神经胶质瘤的发生和发展中起重要作用。然而,其增殖和耐药特性尚不完全清楚。本实验探索了 BTSLCs 的一些生物学特性。从临床获得 20 例不同级别人胶质瘤组织,通过磁珠细胞分选法分离并培养原代胶质瘤细胞,从中分离出 CD133(+)细胞。通过检测 CD133、Nestin、NSE 和 GFAP 的表达以及培养过程来鉴定 BTSLCs。WST-8 试剂盒用于评估不同级别胶质瘤中 CD133(+)细胞的增殖情况,并比较含不同浓度替尼泊苷(VM-26)的培养基中 CD133(+)和 CD133(-)细胞的耐药性。结果显示,CD133(+)细胞可通过自我更新再生,并分别分化为 NSE(+)和 GFAP(+)细胞。高级别胶质瘤中的 CD133(+)细胞比低级别胶质瘤中的细胞增殖更快。含 VM-26 的培养基中存活的 CD133(+)细胞数量明显多于其中的 CD133(-)细胞。因此,提示胶质瘤组织中存在对 VM-26 耐药性更强、更容易在高级别胶质瘤中增殖的 CD133(+) BTSLCs。